Low-Dose Naltrexone: What to Expect Week by Week in Your First Month

What the LDN studies actually measured

The fibromyalgia trials that made LDN well known gave a fixed daily dose, 4.5 mg or 6 mg, and compared it with placebo. The 6 mg trial ran 12 weeks and INNOVA ran 12 months [3][4][5].

LDN is not an FDA-approved product or indication. It means naltrexone at doses far below the approved 50 mg tablet, typically 0.5 to 6 mg a day and most often 4.5 mg, used off-label and supplied mainly through compounding pharmacies [1]. A 2026 narrative review calls the 4.5 mg dose 'empirically derived rather than evidence-based' [1]. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [6].

In month one, watch for the specific things that are documented. HealthRX.com offers low-dose naltrexone by prescription.

The opioid question comes first

Naltrexone is a pure opioid antagonist that blocks opioid effects by competitive binding at opioid receptors [2]. It is contraindicated in patients receiving opioid analgesics, in people currently dependent on opioids (including methadone or buprenorphine maintenance), and in anyone in acute opioid withdrawal [2][7].

The tablet label gives opioid-safety timing rather than any LDN schedule: a minimum of 7 to 10 opioid-free days is recommended for people previously dependent on short-acting opioids, and people switching from buprenorphine or methadone may be vulnerable to withdrawal for as long as 2 weeks [2]. Precipitated withdrawal in the tablet label usually appeared within 5 minutes of ingestion and lasted up to 48 hours, with confusion, somnolence and visual hallucinations, fluid losses needing intravenous fluids, and postmarketing cases that required hospital admission and sometimes intensive care [2]. The Vivitrol label, which covers a different product given as a 380 mg monthly injection, describes the same risk for people who are not opioid-free first [7].

Opioid-containing cough, cold and antidiarrheal products count too. Naltrexone antagonizes them, so they may not work, and the label names tramadol in the opioid-free requirement [2].

A meta-analysis of 4 randomized fibromyalgia trials with 222 patients found more vivid dreams and nausea with LDN than placebo, with no significant difference in serious adverse events [8].

What the 50 mg tablet label says about early side effects

The tablet label covers 50 mg naltrexone for alcohol dependence and opioid blockade, and it gives no LDN-specific reaction rates [2].

In an open-label safety study of about 570 people with alcoholism, new-onset reactions at 2% or more were nausea 10%, headache 7%, dizziness 4%, nervousness 4%, fatigue 4%, insomnia 3%, vomiting 3%, anxiety 2% and somnolence 2% [2]. The same label notes that naltrexone has not been shown to cause significant increases in complaints in placebo-controlled trials in patients known to be opioid-free for more than 7 to 10 days [2].

Weeks 2 to 4: what a four-week record can show

The 6 mg trial assessed its primary pain outcome at 12 weeks and INNOVA assessed its primary outcome at 3 months, so a change at four weeks is not the measure those trials used [4][5].

A daily record of pain, function, sleep and new symptoms may help you notice changes during the first month: the symptom you want to change, rated the same way each day; what you could and could not do; sleep quality; and any new symptom, logged next to the time of the dose. LDN trials have leaned heavily on patient-reported pain and function [3][5].

How the fibromyalgia results came out

Expectations for month one usually rest on these trials, so the mixed results matter. The first small crossover trial, in 31 women on 4.5 mg daily, found daily pain fell 28.8% on naltrexone versus 18.0% on placebo (P=0.016), with no improvement in fatigue or sleep [3]. The larger later trials did not repeat that. In 99 women on 6 mg daily for 12 weeks, pain fell 1.3 points on LDN and 0.9 on placebo, a between-group difference of -0.34 (95% CI -0.95 to 0.27, p=0.27) [4]. INNOVA, in 98 women on 4.5 mg daily for 12 months, found pain at 3 months fell 0.33 points on LDN and 0.64 on placebo, an adjusted difference of 0.49 (p=0.236) [5]. A meta-analysis of four trials with 222 patients found a small pain benefit (mean difference -0.86, 95% CI -1.20 to -0.51) but no significant difference on the revised Fibromyalgia Impact Questionnaire [8]. A 2026 narrative review of 105 studies, 15 of them randomized, concluded that current evidence does not support routine clinical use of LDN [1].

Longer treatment periods in other conditions

In multiple sclerosis, an 8-week crossover pilot enrolled 80 people and 60 completed; nightly 4.5 mg improved the SF-36 Mental Component Summary by 3.3 points (P=0.04), while high dropout and data errors substantially reduced the trial's statistical power [9]. In Crohn's disease, a 12-week trial of 40 adults with active disease found 88% on 4.5 mg had at least a 70-point fall in CDAI score versus 40% on placebo (p=0.009) [10]. For long COVID, a review searching to May 2026 found no randomized trials, only four uncontrolled before-and-after studies with 155 people using 1 to 6 mg a day [11].

Other safety items to know

Liver injury is a label warning: hepatitis and clinically significant liver dysfunction were seen during development and after marketing, and the Vivitrol label says to discontinue use in the event of symptoms or signs of acute hepatitis [2][7]. Depression, suicide, attempted suicide and suicidal ideation have been reported after marketing; the tablet label says no causal relationship has been demonstrated [2].

Lowered opioid tolerance is the other standing risk. After treatment ends, at the end of a dosing interval, or after a missed dose, a previously tolerated opioid dose can cause fatal overdose, and fatal overdoses have been reported after discontinuing treatment [2][7]. The labels advise strongly considering prescribing naloxone or nalmefene when starting and renewing treatment [2][7].

On interactions, the tablet label states that studies of interactions between naltrexone and non-opioid drugs have not been performed and advises caution with any concomitant drug; combining it with disulfiram is not ordinarily recommended because both can harm the liver [2].